For individuals with type 2 diabetes (T2D), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with a slightly increased risk for incident diabetic retinopathy (DR) and with a ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday.

The findings suggest that while GLP-1 RAs may slightly raise the risk of developing diabetic retinopathy, they do not ...

Patients with type 2 diabetes and atopic dermatitis show higher risk for cardiovascular events, but GLP-1 agonists reduce the ...

GLP-1 receptor agonists such as the popular weight loss/diabetes therapies Mounjaro, developed by Eli Lilly (NYSE:LLY), and ...

GLP-1 receptor agonists may reduce cancer risk among people with obesity or overweight, according to retrospective study results.Adults who used GLP-1 medications exhibited a statistically significant ...

Serena Williams sparked a heated debate after revealing she lost 31 pounds using a GLP-1 drug. While the tennis legend ...

The only safety endpoint associated with GLP-1 receptor agonist use was a 49% increased risk of diabetic retinopathy (aHR, 1.49; 1.11-2.00; P =.008).

GLP-1 RA therapy reduces hidradenitis suppurativa severity, flares, symptoms, and BMI in patients with hidradenitis ...

Glucagon-like peptide 1 receptor agonists, including semaglutide, have increased in use and will continue to increase due to their effectiveness in weight loss.

For older adults with type 2 diabetes, glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with nonarteritic anterior ischemic optic neuropathy (NAION).

GLP-1 receptor agonist users were 1.36 times more likely to develop acne 90 days after starting the medication vs. nonusers. Women were 53% more likely to develop acne vulgaris 1 year after ...